Preventive dual therapy provides modest benefit in SMA type 1 study
Infants with a genetic diagnosis of spinal muscular atrophy (SMA) type 1 who were treated with Evrysdi (risdiplam) or Spinraza (nusinersen) in addition to Zolgensma (onasemnogene abeparvovec) could sit, but not walk, sooner than those on Zolgensma alone. These are the findings of a small study in…